# Yarrow (YARW) — News

YARW · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/yarw/news

## Recent headlines

- [Bellevue Group AG reports 10.6% passive stake in Yarrow Bioscience as of Sept 10 - SEC filing](https://www.ainvest.com/news/bellevue-group-ag-reports-10-6-passive-stake-yarrow-bioscience-sept-10-sec-filing-2610) — AInvest Wire, Oct 7, 2026
  Bellevue Group AG has disclosed a 10.6% passive stake in Yarrow Bioscience as of September 10, 2026, according to a recent SEC filing. The investment, which does not confer voting rights or influence over the company’s operations, is categorized as a passive holding. The filing indicates that the…
- [Yarrow Bioscience offering prices $26.00/shr](https://www.ainvest.com/news/yarrow-bioscience-offering-prices-26-00-shr-2609) — AInvest Wire, Sep 11, 2026
  Yarrow Bioscience (YARW) is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, including Graves disease (GD) and thyroid eye disease (TED). The company is currently developing YB-101 monoclonal antibody therapy , a monoclonal antibody therapy…
- [Yarrow Bioscience is said to offer shares for $26 each](https://www.ainvest.com/news/yarrow-bioscience-offer-shares-26-2609) — AInvest Wire, Sep 10, 2026
  Yarrow Bioscience has announced an initial public offering (IPO) with shares being offered at $26 each, according to recent filings with the Securities and Exchange Commission [1]. The company, which focuses on biotechnology and pharmaceutical development, aims to raise capital to support ongoing…
- [Yarrow Bioscience announces proposed underwritten public offering](https://www.ainvest.com/news/yarrow-bioscience-announces-proposed-underwritten-public-offering-2609) — AInvest Wire, Sep 10, 2026
  Yarrow Bioscience, Inc. (Nasdaq: YARW) has announced the completion of its merger with VYNE Therapeutics Inc., marking a significant step in the development of its lead product candidate, YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody. The…
- [Yarrow Bioscience Inc: net loss totaled $6.5 million for the second quarter of 2026](https://www.ainvest.com/news/yarrow-bioscience-net-loss-totaled-6-5-million-quarter-2026-2608) — AInvest Wire, Aug 13, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).